unknown
Stage
2
Investors
About
Alethio Therapeutics is a biopharmaceutical company focused on developing precision therapies for myeloproliferative neoplasms (MPNs), a group of chronic, incurable blood cancers. The company utilizes its ARTEMIS discovery engine to identify and validate novel targets and develop first-in-class antibody-drug conjugate (ADC) therapies aimed at modifying disease progression.
Explore Alethio Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.